🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06376331
Recruiting Observational

Washed Microbiota Transplantation for Attention-deficit/Hyperactivity Disorder

NCT06376331 · tracked via the Priya Life Science China tracker
Sponsor
The Second Hospital of Nanjing Medical University
Phase
Observational
Started
2024-04-28
Last updated
2026-09-15

Condition(s) studied

Attention-deficit/Hyperactivity Disorder

Investigational drug(s) / intervention(s)

washed microbiota transplantation →

washed microbiota transplantation: The prepared microbiota suspension was infused into the participates' lower gut.

Study summary

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterized by inattention and hyperactivity-impulsivity. ADHD is often accompanied by oppositional defiant disorder and sleep disturbance, and can increase the risk of other psychiatric disorders, functional impairment in academic and occupational performance. Recently, gut microbiota has been implicated in the ADHD via gut-brain axis. In this study, investigators aimed to evaluate the efficacy of WMT for core ADHD symptoms and its comorbidities using specialized questionnaires for ADHD and investigate the underlying mechanism.

Eligibility

Sex
ALL
Min age
3 Years
Max age
17 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Children with an established diagnosis of ADHD according to Diagnostic And Statistical Manual Of Mental Disorders Fifth Edition; 2. Aged 3-17; 3. Received stable treatments for ≥1 month preceding WMT; 4. Did not take medications affecting gut microbiota such as antibiotics and probiotics three months before WMT. Exclusion Criteria: 1. Unable to understand the questionnaires or provide informed consent by the guardian; 2. Diagnosed with a single-gene disorder, psychosis, central nervous system diseases, gastrointestinal diseases including ulcerative colitis, Crohn's disease, celiac disease, or eosinophilic esophagitis; 3. Had severe comorbidities including cardiopulmonary failure, severe liver, and kidney diseases and cancer; 4. Accompanied with other life-threatening disorders required emergency treatment; 5. Unable to tolerate colonoscopy or anesthesia

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Department of Microbiota Medicine & Medical Centre for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu Recruiting
SIR RUN RUN hospital of Nanjing Medical University Nanjing Jiangsu Recruiting

More The Second Hospital of Nanjing Medical University trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06376331 on ClinicalTrials.gov ↗ ← All trials in China